Vol 8, Supplement 4 (December 2019): Translational Lung Cancer Research

Editorial Commentary

The characteristics and prognostic role of thymic epithelial tumors with paraneoplastic autoimmune syndromes
Kyoji Hirai, Jitsuo Usuda
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Pascale Tomasini, Laurent Greillier
Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
Laura Le, Ritchell van Dams, Percy Lee
Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
Rui Li, Steven M. Dubinett
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
Antonio Passaro, Filippo de Marinis
Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?
Maria A. Velez, Timothy F. Burns
Surveillance imaging for non-small cell lung cancer: mounting evidence that less is more
Angel Moran, Megan E. Daly
Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors
Jyoti Malhotra, Salma K. Jabbour, Sharon Pine
Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?
In-Jae Oh
Improving outcomes for brain metastases in EGFR mutated NSCLC
Jennifer W. Carlisle, Suresh S. Ramalingam
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis
Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
Maria Jove, Noelia Vilariño, Ernest Nadal
Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
Satomi Tanaka, Junji Uchino
Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery
Tamar B. Nobel, Prasad S. Adusumilli, Daniela Molena
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Biagio Ricciuti, Giuseppe Lamberti, Fausto Roila, Giulio Metro
Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
Alice Mogenet, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
Jacek Jassem
Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer
Katsuhiro Masago, Yoshitsugu Horio, Shiro Fujita, Yasushi Yatabe
For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)
Kenichi Suda
The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer
Carme Obiols, Sergi Call, Ramon Rami-Porta
KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
Amy Lauren Cummings, Edward B. Garon
Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain
Jose M. Pacheco, Drew Moghanaki
The natural course of incidentally detected, small, subsolid lung nodules—is follow-up needed beyond current guideline recommendations?
Benedikt H. Heidinger, Mario Silva, Constance de Margerie-Mellon, Paul A. VanderLaan, Alexander A. Bankier
Optimal management of pulmonary ground-glass opacity nodules
Yeon Wook Kim, Choon-Taek Lee
Ground glass nodules with 5 years’ stability can grow after 10-year follow-up: do genetic features determine the fate?
Yoshihisa Kobayashi, Tetsuya Mitsudomi
Surveillance of ground glass nodules—when is enough, enough?
Frank C. Detterbeck
Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities
Lynnette Fernandez-Cuesta, Matthieu Foll
Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases
Laura Bonanno, Alberto Pavan, Stefano Indraccolo
Spread through air spaces in lung neuroendocrine tumor
Yuka Kozuma, Gouji Toyokawa, Yuichi Yamada, Fumihiro Shoji, Koji Yamazaki, Yoshinao Oda, Sadanori Takeo
Lung neuroendocrine tumors: a new addition to the evolving list of spread through air spaces
Hironori Uruga, Mari Mino-Kenudson
Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what’s known and what’s next
Tao Jiang, Caicun Zhou, Jie Hu, Yuanlin Song
ERAS in VATS—do we really need to follow the trend?
Hussein Elkhayat, Diego Gonzalez-Rivas
Optimizing selection of candidates for lung cancer screening: role of comorbidity, frailty and life expectancy
Shailesh Advani, Dejana Braithwaite
Text-mining in cancer research may help identify effective treatments
Yi-Wen Hsiao, Tzu-Pin Lu
CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?
Jose Carlos Benitez, Jordi Remon, Benjamin Besse
Importance of semaphorins in cancer immunity
Li-Han Chen, Eric Y. Cuang